Pure Global AI
NCT06385847Recruiting

To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer

Cross-Over Trial to Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer
The First Affiliated Hospital of Xiamen UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Prostate Cancer
Drug/Device/Intervention
Zoladex
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The First Affiliated Hospital of Xiamen University
Location
Xiamen, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
Dec 01, 2025
Enrollment
60 participants
Primary outcome

Patient preference

Summary

The GOMIMP will be a Prospective, Randomized, Cross-over Trial to Explore the Patient
 Preference for Goserelin Microsphere (Zoladex®) Versus Goserelin Implant (LY01005) in
 Patients of Prostate Cancer

ICD-10 classifications
Malignant neoplasm of prostateHyperplasia of prostateDisorder of prostate, unspecifiedOther disorders of prostateCarcinoma in situ: Prostate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06385847
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06385847 through Pure Global AI's free database. This Phase 2 trial is sponsored by The First Affiliated Hospital of Xiamen University and is currently Recruiting. The study focuses on Prostate Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.